Niagen Bioscience, Inc. current report, 14 June 2011

SEC Filing Summary: ChromaDex Corporation (Form 8-K)

Business Context and Reporting Period

This Current Report on Form 8-K was filed by ChromaDex Corporation on June 14, 2011. The filing discloses a scheduled investor presentation by company executives at the Accredited Member Denver Small/Micro Cap Conference held on the same date. The report serves to comply with Regulation FD regarding the dissemination of material non-public information.

Key Financial Metrics

The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a disclosure of an event rather than a financial statement.

Material Changes

No material changes to financial performance or operations are reported in this filing. The document solely announces the availability of investor presentation slides (Exhibit 99.1) and video clips on the company's website.

Guidance, Outlook, and Risks

The filing states that the information contained herein, including the attached presentation slides, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section and is not incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed within the body of this 8-K.

Investor Verification Checklist

  • Verify the content of the Investor Presentation Slides (Exhibit 99.1) attached to the filing for specific business updates.
  • Review the "Investor Relations" section of the company website (www.chromadex.com) for the presentation materials and video clips.
  • Note that the presentation materials are not legally "filed" and may not be incorporated by reference in other SEC documents.
  • Confirm the identity of the authorized signatory, Thomas C. Varvaro, Chief Financial Officer.